Casali, Paolo G <br/><br/>
Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Dec 2015 
 - 4276-83 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2015.62.4304  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Australasia<br/>Chemotherapy, Adjuvant<br/>Disease-Free Survival<br/>European Union<br/>Female<br/>Follow-Up Studies<br/>Gastrointestinal Neoplasms--drug therapy<br/>Gastrointestinal Stromal Tumors--drug therapy<br/>Humans<br/>Imatinib Mesylate--therapeutic use<br/>International Cooperation<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Molecular Targeted Therapy--methods<br/>Neoplasm Recurrence, Local--drug therapy<br/>Odds Ratio<br/>Protein Kinase Inhibitors--therapeutic use<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Salvage Therapy--methods<br/>Treatment Failure